NovoCure (NVCR) Cash from Operations Growth (1y) (2015 - 2026)
NovoCure (NVCR) Cash from Operations Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.44 Bn | 175.14 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.10 Bn | 98.88 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 67.99 Bn | 66.53 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.22 Bn | 44.55 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.26 Bn | 27.15 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.02 Bn | 25.74 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 27.01 Bn | 26.43 Bn | - | - |
| 9 | Koninklijke Philips | 23.74 Bn | 20.62 Bn | 2.07 Bn | 122.43% |
| 10 | NovoCure | 2.02 Bn | 1.58 Bn | 142.48 Mn | 151.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 151.03% |
| Mar 31, 2026 | 62.10% |
| Dec 31, 2025 | -421.70% |
| Sep 30, 2025 | 98.28% |
| Jun 30, 2025 | -826.51% |
| Mar 31, 2025 | -12.96% |
| Dec 31, 2024 | 76.29% |
| Sep 30, 2024 | 153.72% |
| Jun 30, 2024 | 92.44% |
| Mar 31, 2024 | -88.76% |
| Dec 31, 2023 | -292.72% |
| Sep 30, 2023 | -186.15% |
| Jun 30, 2023 | -244.25% |
| Mar 31, 2023 | -353.68% |
| Dec 31, 2022 | -125.74% |
| Sep 30, 2022 | -8.11% |
| Jun 30, 2022 | -39.78% |
| Mar 31, 2022 | -120.74% |
| Dec 31, 2021 | -73.07% |
| Sep 30, 2021 | -21.21% |